Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

deseret biologicals, inc. - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

deseret biologicals, inc - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

apotheca company - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml -     indications:  for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever. indications:   for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; human poliovirus type 3 inactivated; diphtheria toxoid - suspension for injection

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

saol therapeutics inc. - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - hepagam b [hepatitis b immune globulin intravenous (human)] is an intravenous immune globulin indicated for the following: including - acute exposure to hbsag-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.), - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag-positive persons, and - household exposure to persons with acute hbv infection. - individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive hepagam b. - individuals who are deficient in iga may have the potential to develop anti-iga antibodies and have an anaphylactoid reaction. hepagam b contains less than 40 micrograms per milliliter of iga. - hepagam b contains less than 40 micrograms per milliliter of iga. - for postexposure prophylaxis indications, hepagam b must be administered intramuscularly only. in patients who have severe thrombocytopenia or any coagulat

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

kedrion biopharma inc. - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - kedrab is a human rabies immune globulin (hrig) indicated for passive, transient post-exposure prophylaxis (pep) of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. kedrab should be administered concurrently with a full course of rabies vaccine. none. risk summary kedrab has not been studied in pregnant women. therefore, the risk of major birth defects and miscarriage in pregnant women who are exposed to kedrab is unknown. animal developmental or reproduction toxicity studies have not been conducted with kedrab. it is not known whether kedrab can cause harm to the fetus when administered to a pregnant woman or whether kedrab can affect reproductive capacity. in the u.s. general population, the estimated background of major birth defects occurs in 2-4% of the general population and miscarriage occurs in 15-20% of clinically recognized pregnancies. risk summary there is no information regarding the presence of kedrab in human milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for kedrab and any potential adverse effects on the breastfed infant from kedrab or from the underlying maternal condition. safety and effectiveness have been established in children. in a pediatric study of 30 patients ranging in age from 0.5 to 14.9 years, kedrab presented no serious adverse reactions through day 84. of the 30 patients, 28 (93.3%) achieved a day-14 rvna titer ≥0.5 iu/ml, the who recommended level. none of the patients who were followed until the end of the study (28/30 patients) developed rabies infection through day 84. [see clinical trials ( 14)] adverse reactions that occurred in ≥3.3% of patients within the first 14 days of kedrab and the first rabies vaccination administration are listed in section 6.1. the clinical trial conducted in the pediatric population is described in section 14. additional evidence to support the use of kedrab in children comes from real world evidence. based on claims data, 172 u.s. children (≤17 years) were treated with kedrab between 2018-2020. based on center for disease control data, no children in the u.s. treated with post-exposure prophylaxis have been reported to have had rabies between 2018-april 2021. clinical studies of kedrab did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. clinical experience with hrig products has not identified differences in effectiveness between elderly and younger patients (acip) 1 .

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

grifols usa, llc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - xembify® (immune globulin subcutaneous, human – klhw) is a 20% immune globulin solution for subcutaneous injection indicated for treatment of primary humoral immunodeficiency (pi) in patients 2 years of age and older. this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies.[1-4] xembify is contraindicated in: patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. iga deficient patients with antibodies against iga and history of hypersensitivity to human immune globulin treatment. risk summary no human data are available to indicate the presence or absence of drug associated risk. animal reproduction studies have not been conducted with xembify. it is not known whether xembify can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. immune globulins cross the placenta from m

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

saol therapeutics inc. - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - hepagam b [hepatitis b immune globulin intravenous (human)] is an intravenous or intramuscular immune globulin indicated for the following: including - acute exposure to hbsag-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.), - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag-positive persons, and - household exposure to persons with acute hbv infection. - individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive hepagam b. - individuals who are deficient in iga may have the potential to develop anti-iga antibodies and have an anaphylactoid reaction. hepagam b contains less than 40 micrograms per milliliter of iga. - hepagam b contains less than 40 micrograms per milliliter of iga. - for postexposure prophylaxis indications, hepagam b must be administered intramuscularly only. in patients who have severe thrombocytopeni

Саудијска Арабија - Енглески - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

human bioplazma llc, hungary - albumin human - solution - 20 %

Саудијска Арабија - Енглески - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

human bioplazma llc, hungary - albumin human - solution - 20 %